nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—Diphenhydramine—allergic rhinitis	0.369	1	CrCtD
Atomoxetine—HTR6—Cyproheptadine—allergic rhinitis	0.0477	0.213	CbGbCtD
Atomoxetine—HTR2C—Cyproheptadine—allergic rhinitis	0.0277	0.124	CbGbCtD
Atomoxetine—SLC6A2—Cyproheptadine—allergic rhinitis	0.0277	0.124	CbGbCtD
Atomoxetine—Protriptyline—Cyproheptadine—allergic rhinitis	0.0252	0.0771	CrCrCtD
Atomoxetine—HTR2A—Cyproheptadine—allergic rhinitis	0.025	0.112	CbGbCtD
Atomoxetine—Nortriptyline—Olopatadine—allergic rhinitis	0.0209	0.064	CrCrCtD
Atomoxetine—Reboxetine—Diphenhydramine—allergic rhinitis	0.0196	0.06	CrCrCtD
Atomoxetine—Benzatropine—Dimenhydrinate—allergic rhinitis	0.0166	0.0506	CrCrCtD
Atomoxetine—Nortriptyline—Cyproheptadine—allergic rhinitis	0.0166	0.0506	CrCrCtD
Atomoxetine—CYP2C19—Desloratadine—allergic rhinitis	0.0144	0.0644	CbGbCtD
Atomoxetine—Eprazinone—Cetirizine—allergic rhinitis	0.014	0.0428	CrCrCtD
Atomoxetine—Phenindione—Cyproheptadine—allergic rhinitis	0.0137	0.0417	CrCrCtD
Atomoxetine—Diphenylpyraline—Cyproheptadine—allergic rhinitis	0.0117	0.0357	CrCrCtD
Atomoxetine—Diphenylpyraline—Dimenhydrinate—allergic rhinitis	0.0117	0.0357	CrCrCtD
Atomoxetine—Modafinil—Dimenhydrinate—allergic rhinitis	0.0114	0.0349	CrCrCtD
Atomoxetine—CYP2D6—Desloratadine—allergic rhinitis	0.011	0.0489	CbGbCtD
Atomoxetine—Bromodiphenhydramine—Dimenhydrinate—allergic rhinitis	0.0109	0.0334	CrCrCtD
Atomoxetine—Cyclizine—Dimenhydrinate—allergic rhinitis	0.0105	0.032	CrCrCtD
Atomoxetine—Cyclizine—Cyproheptadine—allergic rhinitis	0.0105	0.032	CrCrCtD
Atomoxetine—Bromodiphenhydramine—Cetirizine—allergic rhinitis	0.0099	0.0303	CrCrCtD
Atomoxetine—Warfarin—Diphenhydramine—allergic rhinitis	0.00966	0.0295	CrCrCtD
Atomoxetine—Cyclizine—Cetirizine—allergic rhinitis	0.0095	0.029	CrCrCtD
Atomoxetine—Orphenadrine—Dimenhydrinate—allergic rhinitis	0.00859	0.0262	CrCrCtD
Atomoxetine—CYP2C19—Loratadine—allergic rhinitis	0.00828	0.037	CbGbCtD
Atomoxetine—CYP2C19—Diphenhydramine—allergic rhinitis	0.00828	0.037	CbGbCtD
Atomoxetine—Phenprocoumon—Diphenhydramine—allergic rhinitis	0.00816	0.0249	CrCrCtD
Atomoxetine—Benzatropine—Diphenhydramine—allergic rhinitis	0.00786	0.024	CrCrCtD
Atomoxetine—Diphenhydramine—Dimenhydrinate—allergic rhinitis	0.00762	0.0233	CrCrCtD
Atomoxetine—Eprazinone—Diphenhydramine—allergic rhinitis	0.00733	0.0224	CrCrCtD
Atomoxetine—CYP3A4—Flunisolide—allergic rhinitis	0.00697	0.0311	CbGbCtD
Atomoxetine—CYP3A4—Olopatadine—allergic rhinitis	0.00655	0.0293	CbGbCtD
Atomoxetine—Fenoprofen—Diphenhydramine—allergic rhinitis	0.0063	0.0192	CrCrCtD
Atomoxetine—CYP2D6—Loratadine—allergic rhinitis	0.0063	0.0281	CbGbCtD
Atomoxetine—CYP2D6—Diphenhydramine—allergic rhinitis	0.0063	0.0281	CbGbCtD
Atomoxetine—Doxylamine—Diphenhydramine—allergic rhinitis	0.00613	0.0187	CrCrCtD
Atomoxetine—Phenoxybenzamine—Diphenhydramine—allergic rhinitis	0.00582	0.0178	CrCrCtD
Atomoxetine—Diphenylpyraline—Diphenhydramine—allergic rhinitis	0.00555	0.0169	CrCrCtD
Atomoxetine—Modafinil—Diphenhydramine—allergic rhinitis	0.00542	0.0166	CrCrCtD
Atomoxetine—Bromodiphenhydramine—Diphenhydramine—allergic rhinitis	0.00518	0.0158	CrCrCtD
Atomoxetine—Pheniramine—Diphenhydramine—allergic rhinitis	0.00508	0.0155	CrCrCtD
Atomoxetine—Cyclizine—Diphenhydramine—allergic rhinitis	0.00497	0.0152	CrCrCtD
Atomoxetine—Methadone—Diphenhydramine—allergic rhinitis	0.00487	0.0149	CrCrCtD
Atomoxetine—Clofedanol—Diphenhydramine—allergic rhinitis	0.00421	0.0129	CrCrCtD
Atomoxetine—Orphenadrine—Diphenhydramine—allergic rhinitis	0.00407	0.0124	CrCrCtD
Atomoxetine—Benzphetamine—Diphenhydramine—allergic rhinitis	0.00407	0.0124	CrCrCtD
Atomoxetine—CYP3A4—Loratadine—allergic rhinitis	0.004	0.0179	CbGbCtD
Atomoxetine—CYP3A4—Montelukast—allergic rhinitis	0.004	0.0179	CbGbCtD
Atomoxetine—Benzyl Benzoate—Diphenhydramine—allergic rhinitis	0.00378	0.0115	CrCrCtD
Atomoxetine—CYP3A4—Methylprednisolone—allergic rhinitis	0.00366	0.0163	CbGbCtD
Atomoxetine—CYP2C19—Dexamethasone—allergic rhinitis	0.00286	0.0128	CbGbCtD
Atomoxetine—CYP3A4—Triamcinolone—allergic rhinitis	0.00277	0.0124	CbGbCtD
Atomoxetine—CYP3A4—Betamethasone—allergic rhinitis	0.00238	0.0106	CbGbCtD
Atomoxetine—CYP3A4—Prednisolone—allergic rhinitis	0.00235	0.0105	CbGbCtD
Atomoxetine—CYP3A4—Hydrocortisone—allergic rhinitis	0.00223	0.00994	CbGbCtD
Atomoxetine—CYP2D6—Dexamethasone—allergic rhinitis	0.00218	0.00972	CbGbCtD
Atomoxetine—CYP3A4—Dexamethasone—allergic rhinitis	0.00138	0.00618	CbGbCtD
Atomoxetine—NPY1R—G alpha (i) signalling events—PTGDR2—allergic rhinitis	0.000128	0.0329	CbGpPWpGaD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	0.000119	0.0306	CbGpPWpGaD
Atomoxetine—NPY1R—Peptide ligand-binding receptors—CCL11—allergic rhinitis	0.000115	0.0296	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	0.000102	0.0262	CbGpPWpGaD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	9.35e-05	0.024	CbGpPWpGaD
Atomoxetine—NPY1R—Peptide ligand-binding receptors—TAC1—allergic rhinitis	8.38e-05	0.0215	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	8.01e-05	0.0206	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—PTGDR2—allergic rhinitis	7.77e-05	0.0199	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	7.74e-05	0.0199	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—CYSLTR1—allergic rhinitis	6.1e-05	0.0157	CbGpPWpGaD
Atomoxetine—Fatigue—Montelukast—allergic rhinitis	6.05e-05	0.000797	CcSEcCtD
Atomoxetine—Weight decreased—Hydrocortisone—allergic rhinitis	6.03e-05	0.000795	CcSEcCtD
Atomoxetine—Asthenia—Cetirizine—allergic rhinitis	6e-05	0.000791	CcSEcCtD
Atomoxetine—Pain—Montelukast—allergic rhinitis	6e-05	0.000791	CcSEcCtD
Atomoxetine—Infestation NOS—Hydrocortisone—allergic rhinitis	5.94e-05	0.000783	CcSEcCtD
Atomoxetine—Infestation—Hydrocortisone—allergic rhinitis	5.94e-05	0.000783	CcSEcCtD
Atomoxetine—Pruritus—Cetirizine—allergic rhinitis	5.92e-05	0.00078	CcSEcCtD
Atomoxetine—Conjunctivitis—Prednisolone—allergic rhinitis	5.91e-05	0.000779	CcSEcCtD
Atomoxetine—Asthenia—Flunisolide—allergic rhinitis	5.9e-05	0.000778	CcSEcCtD
Atomoxetine—NPY1R—GPCR ligand binding—CCL11—allergic rhinitis	5.89e-05	0.0151	CbGpPWpGaD
Atomoxetine—Dizziness—Loratadine—allergic rhinitis	5.88e-05	0.000775	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Triamcinolone—allergic rhinitis	5.83e-05	0.000769	CcSEcCtD
Atomoxetine—Pruritus—Flunisolide—allergic rhinitis	5.82e-05	0.000767	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Montelukast—allergic rhinitis	5.74e-05	0.000756	CcSEcCtD
Atomoxetine—Diarrhoea—Cetirizine—allergic rhinitis	5.73e-05	0.000755	CcSEcCtD
Atomoxetine—Vomiting—Loratadine—allergic rhinitis	5.65e-05	0.000745	CcSEcCtD
Atomoxetine—Diarrhoea—Flunisolide—allergic rhinitis	5.63e-05	0.000742	CcSEcCtD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	5.62e-05	0.0144	CbGpPWpGaD
Atomoxetine—Rash—Loratadine—allergic rhinitis	5.61e-05	0.000739	CcSEcCtD
Atomoxetine—Dermatitis—Loratadine—allergic rhinitis	5.6e-05	0.000738	CcSEcCtD
Atomoxetine—Infestation—Methylprednisolone—allergic rhinitis	5.58e-05	0.000736	CcSEcCtD
Atomoxetine—Infestation NOS—Methylprednisolone—allergic rhinitis	5.58e-05	0.000736	CcSEcCtD
Atomoxetine—Urticaria—Montelukast—allergic rhinitis	5.57e-05	0.000735	CcSEcCtD
Atomoxetine—Headache—Loratadine—allergic rhinitis	5.57e-05	0.000734	CcSEcCtD
Atomoxetine—Body temperature increased—Montelukast—allergic rhinitis	5.55e-05	0.000731	CcSEcCtD
Atomoxetine—Abdominal pain—Montelukast—allergic rhinitis	5.55e-05	0.000731	CcSEcCtD
Atomoxetine—Sweating increased—Dexamethasone—allergic rhinitis	5.55e-05	0.000731	CcSEcCtD
Atomoxetine—Sweating increased—Betamethasone—allergic rhinitis	5.55e-05	0.000731	CcSEcCtD
Atomoxetine—Dizziness—Cetirizine—allergic rhinitis	5.53e-05	0.000729	CcSEcCtD
Atomoxetine—Dizziness—Flunisolide—allergic rhinitis	5.44e-05	0.000717	CcSEcCtD
Atomoxetine—Conjunctivitis—Triamcinolone—allergic rhinitis	5.44e-05	0.000717	CcSEcCtD
Atomoxetine—Vomiting—Cetirizine—allergic rhinitis	5.32e-05	0.000701	CcSEcCtD
Atomoxetine—Hallucination—Hydrocortisone—allergic rhinitis	5.31e-05	0.000699	CcSEcCtD
Atomoxetine—Nausea—Loratadine—allergic rhinitis	5.28e-05	0.000696	CcSEcCtD
Atomoxetine—Rash—Cetirizine—allergic rhinitis	5.28e-05	0.000695	CcSEcCtD
Atomoxetine—Dermatitis—Cetirizine—allergic rhinitis	5.27e-05	0.000695	CcSEcCtD
Atomoxetine—Headache—Cetirizine—allergic rhinitis	5.24e-05	0.000691	CcSEcCtD
Atomoxetine—Vomiting—Flunisolide—allergic rhinitis	5.23e-05	0.00069	CcSEcCtD
Atomoxetine—Rash—Flunisolide—allergic rhinitis	5.19e-05	0.000684	CcSEcCtD
Atomoxetine—Dermatitis—Flunisolide—allergic rhinitis	5.18e-05	0.000683	CcSEcCtD
Atomoxetine—Headache—Flunisolide—allergic rhinitis	5.15e-05	0.000679	CcSEcCtD
Atomoxetine—Weight decreased—Betamethasone—allergic rhinitis	5.15e-05	0.000679	CcSEcCtD
Atomoxetine—Weight decreased—Dexamethasone—allergic rhinitis	5.15e-05	0.000679	CcSEcCtD
Atomoxetine—Asthenia—Montelukast—allergic rhinitis	5.03e-05	0.000664	CcSEcCtD
Atomoxetine—Hallucination—Methylprednisolone—allergic rhinitis	4.99e-05	0.000657	CcSEcCtD
Atomoxetine—Nausea—Cetirizine—allergic rhinitis	4.97e-05	0.000655	CcSEcCtD
Atomoxetine—Pruritus—Montelukast—allergic rhinitis	4.96e-05	0.000654	CcSEcCtD
Atomoxetine—Conjunctivitis—Betamethasone—allergic rhinitis	4.93e-05	0.00065	CcSEcCtD
Atomoxetine—Conjunctivitis—Dexamethasone—allergic rhinitis	4.93e-05	0.00065	CcSEcCtD
Atomoxetine—Nausea—Flunisolide—allergic rhinitis	4.89e-05	0.000644	CcSEcCtD
Atomoxetine—Diarrhoea—Montelukast—allergic rhinitis	4.8e-05	0.000633	CcSEcCtD
Atomoxetine—HTR1D—G alpha (i) signalling events—PTGDR2—allergic rhinitis	4.7e-05	0.0121	CbGpPWpGaD
Atomoxetine—Mental disorder—Hydrocortisone—allergic rhinitis	4.67e-05	0.000616	CcSEcCtD
Atomoxetine—Cardiac disorder—Methylprednisolone—allergic rhinitis	4.65e-05	0.000613	CcSEcCtD
Atomoxetine—Malnutrition—Hydrocortisone—allergic rhinitis	4.64e-05	0.000612	CcSEcCtD
Atomoxetine—Dizziness—Montelukast—allergic rhinitis	4.64e-05	0.000612	CcSEcCtD
Atomoxetine—HTR1B—G alpha (i) signalling events—PTGDR2—allergic rhinitis	4.6e-05	0.0118	CbGpPWpGaD
Atomoxetine—Angiopathy—Methylprednisolone—allergic rhinitis	4.55e-05	0.000599	CcSEcCtD
Atomoxetine—Hallucination—Dexamethasone—allergic rhinitis	4.53e-05	0.000598	CcSEcCtD
Atomoxetine—Hallucination—Betamethasone—allergic rhinitis	4.53e-05	0.000598	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methylprednisolone—allergic rhinitis	4.52e-05	0.000595	CcSEcCtD
Atomoxetine—Vision blurred—Prednisolone—allergic rhinitis	4.48e-05	0.000591	CcSEcCtD
Atomoxetine—Vomiting—Montelukast—allergic rhinitis	4.46e-05	0.000588	CcSEcCtD
Atomoxetine—Rash—Montelukast—allergic rhinitis	4.42e-05	0.000583	CcSEcCtD
Atomoxetine—Dermatitis—Montelukast—allergic rhinitis	4.42e-05	0.000583	CcSEcCtD
Atomoxetine—Headache—Montelukast—allergic rhinitis	4.4e-05	0.000579	CcSEcCtD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	4.4e-05	0.0113	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—PTGDR2—allergic rhinitis	4.39e-05	0.0113	CbGpPWpGaD
Atomoxetine—Mental disorder—Methylprednisolone—allergic rhinitis	4.39e-05	0.000579	CcSEcCtD
Atomoxetine—Malnutrition—Methylprednisolone—allergic rhinitis	4.36e-05	0.000575	CcSEcCtD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	4.36e-05	0.0112	CbGpPWpGaD
Atomoxetine—Dysgeusia—Triamcinolone—allergic rhinitis	4.28e-05	0.000564	CcSEcCtD
Atomoxetine—NPY1R—GPCR ligand binding—TAC1—allergic rhinitis	4.28e-05	0.011	CbGpPWpGaD
Atomoxetine—Vertigo—Prednisolone—allergic rhinitis	4.27e-05	0.000563	CcSEcCtD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	4.27e-05	0.011	CbGpPWpGaD
Atomoxetine—Syncope—Prednisolone—allergic rhinitis	4.26e-05	0.000562	CcSEcCtD
Atomoxetine—Back pain—Triamcinolone—allergic rhinitis	4.23e-05	0.000557	CcSEcCtD
Atomoxetine—Loss of consciousness—Prednisolone—allergic rhinitis	4.18e-05	0.000551	CcSEcCtD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—IL13—allergic rhinitis	4.18e-05	0.0107	CbGpPWpGaD
Atomoxetine—Vertigo—Hydrocortisone—allergic rhinitis	4.17e-05	0.00055	CcSEcCtD
Atomoxetine—Nausea—Montelukast—allergic rhinitis	4.17e-05	0.000549	CcSEcCtD
Atomoxetine—Syncope—Hydrocortisone—allergic rhinitis	4.16e-05	0.000549	CcSEcCtD
Atomoxetine—Angiopathy—Dexamethasone—allergic rhinitis	4.13e-05	0.000545	CcSEcCtD
Atomoxetine—Angiopathy—Betamethasone—allergic rhinitis	4.13e-05	0.000545	CcSEcCtD
Atomoxetine—Convulsion—Prednisolone—allergic rhinitis	4.12e-05	0.000543	CcSEcCtD
Atomoxetine—Loss of consciousness—Hydrocortisone—allergic rhinitis	4.08e-05	0.000538	CcSEcCtD
Atomoxetine—Convulsion—Hydrocortisone—allergic rhinitis	4.02e-05	0.00053	CcSEcCtD
Atomoxetine—NPY1R—Signaling by GPCR—PTGDR2—allergic rhinitis	3.99e-05	0.0102	CbGpPWpGaD
Atomoxetine—Myalgia—Hydrocortisone—allergic rhinitis	3.95e-05	0.000521	CcSEcCtD
Atomoxetine—Anxiety—Hydrocortisone—allergic rhinitis	3.94e-05	0.000519	CcSEcCtD
Atomoxetine—Vertigo—Triamcinolone—allergic rhinitis	3.93e-05	0.000518	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—allergic rhinitis	3.93e-05	0.000517	CcSEcCtD
Atomoxetine—Syncope—Triamcinolone—allergic rhinitis	3.92e-05	0.000517	CcSEcCtD
Atomoxetine—Vertigo—Methylprednisolone—allergic rhinitis	3.92e-05	0.000517	CcSEcCtD
Atomoxetine—Syncope—Methylprednisolone—allergic rhinitis	3.91e-05	0.000516	CcSEcCtD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—TAC1—allergic rhinitis	3.85e-05	0.00987	CbGpPWpGaD
Atomoxetine—Loss of consciousness—Triamcinolone—allergic rhinitis	3.84e-05	0.000506	CcSEcCtD
Atomoxetine—Loss of consciousness—Methylprednisolone—allergic rhinitis	3.83e-05	0.000505	CcSEcCtD
Atomoxetine—Shock—Prednisolone—allergic rhinitis	3.82e-05	0.000503	CcSEcCtD
Atomoxetine—Cough—Triamcinolone—allergic rhinitis	3.82e-05	0.000503	CcSEcCtD
Atomoxetine—Convulsion—Triamcinolone—allergic rhinitis	3.79e-05	0.000499	CcSEcCtD
Atomoxetine—Tachycardia—Prednisolone—allergic rhinitis	3.79e-05	0.000499	CcSEcCtD
Atomoxetine—Convulsion—Methylprednisolone—allergic rhinitis	3.78e-05	0.000498	CcSEcCtD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	3.77e-05	0.00966	CbGpPWpGaD
Atomoxetine—Infection—Hydrocortisone—allergic rhinitis	3.76e-05	0.000496	CcSEcCtD
Atomoxetine—Hyperhidrosis—Prednisolone—allergic rhinitis	3.75e-05	0.000494	CcSEcCtD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	3.74e-05	0.00959	CbGpPWpGaD
Atomoxetine—Shock—Hydrocortisone—allergic rhinitis	3.73e-05	0.000491	CcSEcCtD
Atomoxetine—Myalgia—Triamcinolone—allergic rhinitis	3.72e-05	0.000491	CcSEcCtD
Atomoxetine—Nervous system disorder—Hydrocortisone—allergic rhinitis	3.72e-05	0.00049	CcSEcCtD
Atomoxetine—Arthralgia—Methylprednisolone—allergic rhinitis	3.71e-05	0.000489	CcSEcCtD
Atomoxetine—Myalgia—Methylprednisolone—allergic rhinitis	3.71e-05	0.000489	CcSEcCtD
Atomoxetine—Anxiety—Methylprednisolone—allergic rhinitis	3.7e-05	0.000488	CcSEcCtD
Atomoxetine—Tachycardia—Hydrocortisone—allergic rhinitis	3.7e-05	0.000487	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—allergic rhinitis	3.69e-05	0.000486	CcSEcCtD
Atomoxetine—Skin disorder—Hydrocortisone—allergic rhinitis	3.68e-05	0.000485	CcSEcCtD
Atomoxetine—Hyperhidrosis—Hydrocortisone—allergic rhinitis	3.66e-05	0.000483	CcSEcCtD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	3.66e-05	0.00939	CbGpPWpGaD
Atomoxetine—Dry mouth—Triamcinolone—allergic rhinitis	3.64e-05	0.00048	CcSEcCtD
Atomoxetine—Anorexia—Hydrocortisone—allergic rhinitis	3.61e-05	0.000476	CcSEcCtD
Atomoxetine—Vertigo—Dexamethasone—allergic rhinitis	3.56e-05	0.00047	CcSEcCtD
Atomoxetine—Vertigo—Betamethasone—allergic rhinitis	3.56e-05	0.00047	CcSEcCtD
Atomoxetine—Syncope—Betamethasone—allergic rhinitis	3.56e-05	0.000469	CcSEcCtD
Atomoxetine—Syncope—Dexamethasone—allergic rhinitis	3.56e-05	0.000469	CcSEcCtD
Atomoxetine—Infection—Triamcinolone—allergic rhinitis	3.54e-05	0.000467	CcSEcCtD
Atomoxetine—Infection—Methylprednisolone—allergic rhinitis	3.54e-05	0.000466	CcSEcCtD
Atomoxetine—Shock—Triamcinolone—allergic rhinitis	3.51e-05	0.000463	CcSEcCtD
Atomoxetine—Insomnia—Prednisolone—allergic rhinitis	3.51e-05	0.000463	CcSEcCtD
Atomoxetine—Shock—Methylprednisolone—allergic rhinitis	3.5e-05	0.000462	CcSEcCtD
Atomoxetine—Nervous system disorder—Methylprednisolone—allergic rhinitis	3.49e-05	0.00046	CcSEcCtD
Atomoxetine—Loss of consciousness—Dexamethasone—allergic rhinitis	3.49e-05	0.00046	CcSEcCtD
Atomoxetine—Loss of consciousness—Betamethasone—allergic rhinitis	3.49e-05	0.00046	CcSEcCtD
Atomoxetine—Paraesthesia—Prednisolone—allergic rhinitis	3.48e-05	0.000459	CcSEcCtD
Atomoxetine—Tachycardia—Triamcinolone—allergic rhinitis	3.48e-05	0.000459	CcSEcCtD
Atomoxetine—Tachycardia—Methylprednisolone—allergic rhinitis	3.47e-05	0.000458	CcSEcCtD
Atomoxetine—Skin disorder—Methylprednisolone—allergic rhinitis	3.46e-05	0.000456	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Hydrocortisone—allergic rhinitis	3.45e-05	0.000455	CcSEcCtD
Atomoxetine—Hyperhidrosis—Triamcinolone—allergic rhinitis	3.45e-05	0.000455	CcSEcCtD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	3.45e-05	0.00885	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—CYSLTR1—allergic rhinitis	3.45e-05	0.00885	CbGpPWpGaD
Atomoxetine—Hyperhidrosis—Methylprednisolone—allergic rhinitis	3.44e-05	0.000454	CcSEcCtD
Atomoxetine—Convulsion—Betamethasone—allergic rhinitis	3.44e-05	0.000453	CcSEcCtD
Atomoxetine—Convulsion—Dexamethasone—allergic rhinitis	3.44e-05	0.000453	CcSEcCtD
Atomoxetine—Insomnia—Hydrocortisone—allergic rhinitis	3.43e-05	0.000452	CcSEcCtD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	3.42e-05	0.00878	CbGpPWpGaD
Atomoxetine—Paraesthesia—Hydrocortisone—allergic rhinitis	3.4e-05	0.000448	CcSEcCtD
Atomoxetine—Myalgia—Betamethasone—allergic rhinitis	3.38e-05	0.000445	CcSEcCtD
Atomoxetine—Myalgia—Dexamethasone—allergic rhinitis	3.38e-05	0.000445	CcSEcCtD
Atomoxetine—Anxiety—Dexamethasone—allergic rhinitis	3.37e-05	0.000444	CcSEcCtD
Atomoxetine—Anxiety—Betamethasone—allergic rhinitis	3.37e-05	0.000444	CcSEcCtD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	3.35e-05	0.0086	CbGpPWpGaD
Atomoxetine—Dyspepsia—Hydrocortisone—allergic rhinitis	3.34e-05	0.00044	CcSEcCtD
Atomoxetine—Pain—Prednisolone—allergic rhinitis	3.32e-05	0.000437	CcSEcCtD
Atomoxetine—Decreased appetite—Hydrocortisone—allergic rhinitis	3.29e-05	0.000434	CcSEcCtD
Atomoxetine—HTR2C—G alpha (q) signalling events—CYSLTR1—allergic rhinitis	3.29e-05	0.00843	CbGpPWpGaD
Atomoxetine—Gastrointestinal disorder—Hydrocortisone—allergic rhinitis	3.27e-05	0.000431	CcSEcCtD
Atomoxetine—Fatigue—Hydrocortisone—allergic rhinitis	3.27e-05	0.000431	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Triamcinolone—allergic rhinitis	3.25e-05	0.000428	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methylprednisolone—allergic rhinitis	3.24e-05	0.000428	CcSEcCtD
Atomoxetine—Pain—Hydrocortisone—allergic rhinitis	3.24e-05	0.000427	CcSEcCtD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	3.24e-05	0.00831	CbGpPWpGaD
Atomoxetine—Insomnia—Triamcinolone—allergic rhinitis	3.23e-05	0.000425	CcSEcCtD
Atomoxetine—Insomnia—Methylprednisolone—allergic rhinitis	3.22e-05	0.000424	CcSEcCtD
Atomoxetine—Infection—Betamethasone—allergic rhinitis	3.22e-05	0.000424	CcSEcCtD
Atomoxetine—Infection—Dexamethasone—allergic rhinitis	3.22e-05	0.000424	CcSEcCtD
Atomoxetine—Paraesthesia—Triamcinolone—allergic rhinitis	3.2e-05	0.000422	CcSEcCtD
Atomoxetine—Feeling abnormal—Prednisolone—allergic rhinitis	3.2e-05	0.000421	CcSEcCtD
Atomoxetine—Paraesthesia—Methylprednisolone—allergic rhinitis	3.2e-05	0.000421	CcSEcCtD
Atomoxetine—Shock—Betamethasone—allergic rhinitis	3.19e-05	0.00042	CcSEcCtD
Atomoxetine—Shock—Dexamethasone—allergic rhinitis	3.19e-05	0.00042	CcSEcCtD
Atomoxetine—Nervous system disorder—Dexamethasone—allergic rhinitis	3.18e-05	0.000418	CcSEcCtD
Atomoxetine—Nervous system disorder—Betamethasone—allergic rhinitis	3.18e-05	0.000418	CcSEcCtD
Atomoxetine—Tachycardia—Dexamethasone—allergic rhinitis	3.16e-05	0.000416	CcSEcCtD
Atomoxetine—Tachycardia—Betamethasone—allergic rhinitis	3.16e-05	0.000416	CcSEcCtD
Atomoxetine—Dyspepsia—Triamcinolone—allergic rhinitis	3.14e-05	0.000414	CcSEcCtD
Atomoxetine—Dyspepsia—Methylprednisolone—allergic rhinitis	3.13e-05	0.000413	CcSEcCtD
Atomoxetine—NPY1R—Signaling by GPCR—CYSLTR1—allergic rhinitis	3.13e-05	0.00803	CbGpPWpGaD
Atomoxetine—Hyperhidrosis—Betamethasone—allergic rhinitis	3.13e-05	0.000413	CcSEcCtD
Atomoxetine—Hyperhidrosis—Dexamethasone—allergic rhinitis	3.13e-05	0.000413	CcSEcCtD
Atomoxetine—Feeling abnormal—Hydrocortisone—allergic rhinitis	3.12e-05	0.000412	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Hydrocortisone—allergic rhinitis	3.1e-05	0.000408	CcSEcCtD
Atomoxetine—Anorexia—Dexamethasone—allergic rhinitis	3.09e-05	0.000407	CcSEcCtD
Atomoxetine—Anorexia—Betamethasone—allergic rhinitis	3.09e-05	0.000407	CcSEcCtD
Atomoxetine—Urticaria—Prednisolone—allergic rhinitis	3.08e-05	0.000406	CcSEcCtD
Atomoxetine—Fatigue—Triamcinolone—allergic rhinitis	3.08e-05	0.000405	CcSEcCtD
Atomoxetine—Fatigue—Methylprednisolone—allergic rhinitis	3.07e-05	0.000405	CcSEcCtD
Atomoxetine—Pain—Triamcinolone—allergic rhinitis	3.05e-05	0.000402	CcSEcCtD
Atomoxetine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—allergic rhinitis	3.03e-05	0.00779	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—CCL11—allergic rhinitis	3.02e-05	0.00776	CbGpPWpGaD
Atomoxetine—Urticaria—Hydrocortisone—allergic rhinitis	3.01e-05	0.000397	CcSEcCtD
Atomoxetine—Abdominal pain—Hydrocortisone—allergic rhinitis	3e-05	0.000395	CcSEcCtD
Atomoxetine—Body temperature increased—Hydrocortisone—allergic rhinitis	3e-05	0.000395	CcSEcCtD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	2.95e-05	0.00758	CbGpPWpGaD
Atomoxetine—Musculoskeletal discomfort—Dexamethasone—allergic rhinitis	2.95e-05	0.000389	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Betamethasone—allergic rhinitis	2.95e-05	0.000389	CcSEcCtD
Atomoxetine—Feeling abnormal—Triamcinolone—allergic rhinitis	2.94e-05	0.000388	CcSEcCtD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CYSLTR1—allergic rhinitis	2.94e-05	0.00754	CbGpPWpGaD
Atomoxetine—Feeling abnormal—Methylprednisolone—allergic rhinitis	2.93e-05	0.000387	CcSEcCtD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	2.93e-05	0.00753	CbGpPWpGaD
Atomoxetine—Insomnia—Dexamethasone—allergic rhinitis	2.93e-05	0.000386	CcSEcCtD
Atomoxetine—Insomnia—Betamethasone—allergic rhinitis	2.93e-05	0.000386	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methylprednisolone—allergic rhinitis	2.91e-05	0.000384	CcSEcCtD
Atomoxetine—Paraesthesia—Dexamethasone—allergic rhinitis	2.91e-05	0.000383	CcSEcCtD
Atomoxetine—Paraesthesia—Betamethasone—allergic rhinitis	2.91e-05	0.000383	CcSEcCtD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	2.87e-05	0.00737	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—PTGDR2—allergic rhinitis	2.87e-05	0.00736	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	2.85e-05	0.00732	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—CYSLTR1—allergic rhinitis	2.85e-05	0.00732	CbGpPWpGaD
Atomoxetine—Dyspepsia—Betamethasone—allergic rhinitis	2.85e-05	0.000376	CcSEcCtD
Atomoxetine—Dyspepsia—Dexamethasone—allergic rhinitis	2.85e-05	0.000376	CcSEcCtD
Atomoxetine—HTR1D—GPCR ligand binding—PTGDR2—allergic rhinitis	2.85e-05	0.0073	CbGpPWpGaD
Atomoxetine—Urticaria—Triamcinolone—allergic rhinitis	2.83e-05	0.000374	CcSEcCtD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	2.83e-05	0.00727	CbGpPWpGaD
Atomoxetine—Urticaria—Methylprednisolone—allergic rhinitis	2.83e-05	0.000373	CcSEcCtD
Atomoxetine—SLC6A4—Circadian rythm related genes—ADIPOQ—allergic rhinitis	2.83e-05	0.00725	CbGpPWpGaD
Atomoxetine—Body temperature increased—Triamcinolone—allergic rhinitis	2.82e-05	0.000372	CcSEcCtD
Atomoxetine—Abdominal pain—Methylprednisolone—allergic rhinitis	2.81e-05	0.000371	CcSEcCtD
Atomoxetine—Decreased appetite—Betamethasone—allergic rhinitis	2.81e-05	0.000371	CcSEcCtD
Atomoxetine—Decreased appetite—Dexamethasone—allergic rhinitis	2.81e-05	0.000371	CcSEcCtD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	2.81e-05	0.00721	CbGpPWpGaD
Atomoxetine—Gastrointestinal disorder—Dexamethasone—allergic rhinitis	2.8e-05	0.000368	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Betamethasone—allergic rhinitis	2.8e-05	0.000368	CcSEcCtD
Atomoxetine—Fatigue—Betamethasone—allergic rhinitis	2.79e-05	0.000368	CcSEcCtD
Atomoxetine—Fatigue—Dexamethasone—allergic rhinitis	2.79e-05	0.000368	CcSEcCtD
Atomoxetine—HTR1B—GPCR ligand binding—PTGDR2—allergic rhinitis	2.79e-05	0.00715	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	2.77e-05	0.00712	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	2.77e-05	0.00712	CbGpPWpGaD
Atomoxetine—Pain—Dexamethasone—allergic rhinitis	2.77e-05	0.000365	CcSEcCtD
Atomoxetine—Pain—Betamethasone—allergic rhinitis	2.77e-05	0.000365	CcSEcCtD
Atomoxetine—Asthenia—Hydrocortisone—allergic rhinitis	2.72e-05	0.000358	CcSEcCtD
Atomoxetine—Pruritus—Hydrocortisone—allergic rhinitis	2.68e-05	0.000353	CcSEcCtD
Atomoxetine—Feeling abnormal—Dexamethasone—allergic rhinitis	2.67e-05	0.000352	CcSEcCtD
Atomoxetine—Feeling abnormal—Betamethasone—allergic rhinitis	2.67e-05	0.000352	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Dexamethasone—allergic rhinitis	2.65e-05	0.000349	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Betamethasone—allergic rhinitis	2.65e-05	0.000349	CcSEcCtD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—IL10—allergic rhinitis	2.61e-05	0.00671	CbGpPWpGaD
Atomoxetine—Diarrhoea—Hydrocortisone—allergic rhinitis	2.59e-05	0.000342	CcSEcCtD
Atomoxetine—Urticaria—Betamethasone—allergic rhinitis	2.57e-05	0.000339	CcSEcCtD
Atomoxetine—Urticaria—Dexamethasone—allergic rhinitis	2.57e-05	0.000339	CcSEcCtD
Atomoxetine—Dizziness—Prednisolone—allergic rhinitis	2.57e-05	0.000338	CcSEcCtD
Atomoxetine—Asthenia—Triamcinolone—allergic rhinitis	2.56e-05	0.000337	CcSEcCtD
Atomoxetine—Abdominal pain—Betamethasone—allergic rhinitis	2.56e-05	0.000337	CcSEcCtD
Atomoxetine—Body temperature increased—Betamethasone—allergic rhinitis	2.56e-05	0.000337	CcSEcCtD
Atomoxetine—Abdominal pain—Dexamethasone—allergic rhinitis	2.56e-05	0.000337	CcSEcCtD
Atomoxetine—Body temperature increased—Dexamethasone—allergic rhinitis	2.56e-05	0.000337	CcSEcCtD
Atomoxetine—Asthenia—Methylprednisolone—allergic rhinitis	2.55e-05	0.000337	CcSEcCtD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CYSLTR1—allergic rhinitis	2.55e-05	0.00655	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	2.54e-05	0.00652	CbGpPWpGaD
Atomoxetine—Pruritus—Triamcinolone—allergic rhinitis	2.52e-05	0.000333	CcSEcCtD
Atomoxetine—Pruritus—Methylprednisolone—allergic rhinitis	2.52e-05	0.000332	CcSEcCtD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL13—allergic rhinitis	2.52e-05	0.00645	CbGpPWpGaD
Atomoxetine—Dizziness—Hydrocortisone—allergic rhinitis	2.51e-05	0.00033	CcSEcCtD
Atomoxetine—Rash—Prednisolone—allergic rhinitis	2.45e-05	0.000322	CcSEcCtD
Atomoxetine—Dermatitis—Prednisolone—allergic rhinitis	2.44e-05	0.000322	CcSEcCtD
Atomoxetine—Diarrhoea—Methylprednisolone—allergic rhinitis	2.44e-05	0.000321	CcSEcCtD
Atomoxetine—Headache—Prednisolone—allergic rhinitis	2.43e-05	0.00032	CcSEcCtD
Atomoxetine—NPY1R—GPCR downstream signaling—TAC1—allergic rhinitis	2.42e-05	0.00621	CbGpPWpGaD
Atomoxetine—Vomiting—Hydrocortisone—allergic rhinitis	2.41e-05	0.000318	CcSEcCtD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	2.41e-05	0.00618	CbGpPWpGaD
Atomoxetine—Rash—Hydrocortisone—allergic rhinitis	2.39e-05	0.000315	CcSEcCtD
Atomoxetine—Dermatitis—Hydrocortisone—allergic rhinitis	2.39e-05	0.000315	CcSEcCtD
Atomoxetine—Headache—Hydrocortisone—allergic rhinitis	2.37e-05	0.000313	CcSEcCtD
Atomoxetine—Dizziness—Triamcinolone—allergic rhinitis	2.36e-05	0.000311	CcSEcCtD
Atomoxetine—NPY1R—Signaling Pathways—PTGDR2—allergic rhinitis	2.36e-05	0.00605	CbGpPWpGaD
Atomoxetine—Dizziness—Methylprednisolone—allergic rhinitis	2.35e-05	0.00031	CcSEcCtD
Atomoxetine—Asthenia—Dexamethasone—allergic rhinitis	2.32e-05	0.000306	CcSEcCtD
Atomoxetine—Asthenia—Betamethasone—allergic rhinitis	2.32e-05	0.000306	CcSEcCtD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—TAC1—allergic rhinitis	2.31e-05	0.00594	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—TAC1—allergic rhinitis	2.31e-05	0.00592	CbGpPWpGaD
Atomoxetine—Nausea—Prednisolone—allergic rhinitis	2.3e-05	0.000304	CcSEcCtD
Atomoxetine—Pruritus—Betamethasone—allergic rhinitis	2.29e-05	0.000302	CcSEcCtD
Atomoxetine—Pruritus—Dexamethasone—allergic rhinitis	2.29e-05	0.000302	CcSEcCtD
Atomoxetine—Vomiting—Triamcinolone—allergic rhinitis	2.27e-05	0.000299	CcSEcCtD
Atomoxetine—Vomiting—Methylprednisolone—allergic rhinitis	2.26e-05	0.000298	CcSEcCtD
Atomoxetine—Nausea—Hydrocortisone—allergic rhinitis	2.25e-05	0.000297	CcSEcCtD
Atomoxetine—HTR6—GPCR ligand binding—CYSLTR1—allergic rhinitis	2.25e-05	0.00577	CbGpPWpGaD
Atomoxetine—Rash—Triamcinolone—allergic rhinitis	2.25e-05	0.000297	CcSEcCtD
Atomoxetine—NPY1R—GPCR downstream signaling—IL5—allergic rhinitis	2.25e-05	0.00577	CbGpPWpGaD
Atomoxetine—Dermatitis—Triamcinolone—allergic rhinitis	2.25e-05	0.000296	CcSEcCtD
Atomoxetine—Rash—Methylprednisolone—allergic rhinitis	2.24e-05	0.000296	CcSEcCtD
Atomoxetine—Dermatitis—Methylprednisolone—allergic rhinitis	2.24e-05	0.000296	CcSEcCtD
Atomoxetine—Headache—Triamcinolone—allergic rhinitis	2.24e-05	0.000295	CcSEcCtD
Atomoxetine—HTR1D—GPCR ligand binding—CYSLTR1—allergic rhinitis	2.23e-05	0.00573	CbGpPWpGaD
Atomoxetine—Headache—Methylprednisolone—allergic rhinitis	2.23e-05	0.000294	CcSEcCtD
Atomoxetine—Diarrhoea—Dexamethasone—allergic rhinitis	2.22e-05	0.000292	CcSEcCtD
Atomoxetine—Diarrhoea—Betamethasone—allergic rhinitis	2.22e-05	0.000292	CcSEcCtD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	2.21e-05	0.00566	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—TAC1—allergic rhinitis	2.2e-05	0.00564	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CYSLTR1—allergic rhinitis	2.19e-05	0.00561	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	2.18e-05	0.00558	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CCL11—allergic rhinitis	2.17e-05	0.00558	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CCL11—allergic rhinitis	2.16e-05	0.00553	CbGpPWpGaD
Atomoxetine—Dizziness—Betamethasone—allergic rhinitis	2.14e-05	0.000282	CcSEcCtD
Atomoxetine—Dizziness—Dexamethasone—allergic rhinitis	2.14e-05	0.000282	CcSEcCtD
Atomoxetine—Nausea—Triamcinolone—allergic rhinitis	2.12e-05	0.000279	CcSEcCtD
Atomoxetine—Nausea—Methylprednisolone—allergic rhinitis	2.11e-05	0.000279	CcSEcCtD
Atomoxetine—HTR2C—GPCR ligand binding—PTGDR2—allergic rhinitis	2.11e-05	0.00542	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CCL11—allergic rhinitis	2.11e-05	0.00542	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	2.1e-05	0.00539	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	2.07e-05	0.00532	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—allergic rhinitis	2.06e-05	0.00529	CbGpPWpGaD
Atomoxetine—Vomiting—Betamethasone—allergic rhinitis	2.06e-05	0.000271	CcSEcCtD
Atomoxetine—Vomiting—Dexamethasone—allergic rhinitis	2.06e-05	0.000271	CcSEcCtD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	2.06e-05	0.00528	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL5—allergic rhinitis	2.04e-05	0.00524	CbGpPWpGaD
Atomoxetine—Rash—Betamethasone—allergic rhinitis	2.04e-05	0.000269	CcSEcCtD
Atomoxetine—Rash—Dexamethasone—allergic rhinitis	2.04e-05	0.000269	CcSEcCtD
Atomoxetine—Dermatitis—Betamethasone—allergic rhinitis	2.04e-05	0.000269	CcSEcCtD
Atomoxetine—Dermatitis—Dexamethasone—allergic rhinitis	2.04e-05	0.000269	CcSEcCtD
Atomoxetine—Headache—Betamethasone—allergic rhinitis	2.03e-05	0.000267	CcSEcCtD
Atomoxetine—Headache—Dexamethasone—allergic rhinitis	2.03e-05	0.000267	CcSEcCtD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	2.01e-05	0.00517	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—TAC1—allergic rhinitis	2e-05	0.00514	CbGpPWpGaD
Atomoxetine—Nausea—Dexamethasone—allergic rhinitis	1.92e-05	0.000253	CcSEcCtD
Atomoxetine—Nausea—Betamethasone—allergic rhinitis	1.92e-05	0.000253	CcSEcCtD
Atomoxetine—CYP2C19—Melatonin metabolism and effects—NFKB1—allergic rhinitis	1.91e-05	0.00489	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	1.89e-05	0.00485	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CYSLTR1—allergic rhinitis	1.85e-05	0.00475	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—PTGDR2—allergic rhinitis	1.83e-05	0.00471	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	1.82e-05	0.00468	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—allergic rhinitis	1.79e-05	0.0046	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCL11—allergic rhinitis	1.79e-05	0.00458	CbGpPWpGaD
Atomoxetine—CYP2D6—Melatonin metabolism and effects—NFKB1—allergic rhinitis	1.75e-05	0.0045	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CYSLTR1—allergic rhinitis	1.66e-05	0.00425	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PTGDR2—allergic rhinitis	1.62e-05	0.00416	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PTGDR2—allergic rhinitis	1.61e-05	0.00413	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CCL11—allergic rhinitis	1.6e-05	0.00411	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—TAC1—allergic rhinitis	1.58e-05	0.00405	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PTGDR2—allergic rhinitis	1.57e-05	0.00404	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL10—allergic rhinitis	1.57e-05	0.00404	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—TAC1—allergic rhinitis	1.57e-05	0.00402	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—TAC1—allergic rhinitis	1.53e-05	0.00394	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	1.53e-05	0.00392	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PTGDR2—allergic rhinitis	1.47e-05	0.00378	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PTGDR2—allergic rhinitis	1.46e-05	0.00375	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CYSLTR1—allergic rhinitis	1.44e-05	0.00369	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PTGDR2—allergic rhinitis	1.43e-05	0.00367	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CCL11—allergic rhinitis	1.39e-05	0.00357	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	1.33e-05	0.0034	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TAC1—allergic rhinitis	1.3e-05	0.00333	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—allergic rhinitis	1.28e-05	0.00328	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CYSLTR1—allergic rhinitis	1.27e-05	0.00326	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CYSLTR1—allergic rhinitis	1.26e-05	0.00324	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CYSLTR1—allergic rhinitis	1.24e-05	0.00317	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL5—allergic rhinitis	1.21e-05	0.0031	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PTGDR2—allergic rhinitis	1.19e-05	0.00306	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—TAC1—allergic rhinitis	1.16e-05	0.00298	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CYSLTR1—allergic rhinitis	1.15e-05	0.00296	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CYSLTR1—allergic rhinitis	1.15e-05	0.00294	CbGpPWpGaD
Atomoxetine—SLC6A4—NRF2 pathway—TGFB1—allergic rhinitis	1.12e-05	0.00288	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CYSLTR1—allergic rhinitis	1.12e-05	0.00288	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCL11—allergic rhinitis	1.12e-05	0.00286	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCL11—allergic rhinitis	1.11e-05	0.00284	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PTGDR2—allergic rhinitis	1.08e-05	0.00278	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCL11—allergic rhinitis	1.08e-05	0.00278	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PTGDR2—allergic rhinitis	1.04e-05	0.00266	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—TAC1—allergic rhinitis	1.01e-05	0.00259	CbGpPWpGaD
Atomoxetine—SLC6A2—NRF2 pathway—TGFB1—allergic rhinitis	9.66e-06	0.00248	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTGDR2—allergic rhinitis	9.41e-06	0.00242	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CYSLTR1—allergic rhinitis	9.36e-06	0.0024	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—TAC1—allergic rhinitis	8.92e-06	0.00229	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—TAC1—allergic rhinitis	8.86e-06	0.00227	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTGDR2—allergic rhinitis	8.69e-06	0.00223	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—TAC1—allergic rhinitis	8.67e-06	0.00223	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTGDR2—allergic rhinitis	8.63e-06	0.00221	CbGpPWpGaD
Atomoxetine—SLC6A3—NRF2 pathway—TGFB1—allergic rhinitis	8.56e-06	0.0022	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CYSLTR1—allergic rhinitis	8.5e-06	0.00218	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SMAD3—allergic rhinitis	8.49e-06	0.00218	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTGDR2—allergic rhinitis	8.45e-06	0.00217	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—IL5—allergic rhinitis	8.3e-06	0.00213	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL5—allergic rhinitis	8.23e-06	0.00211	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL11—allergic rhinitis	8.21e-06	0.00211	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CYSLTR1—allergic rhinitis	8.13e-06	0.00209	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TAC1—allergic rhinitis	8.1e-06	0.00208	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL5—allergic rhinitis	8.06e-06	0.00207	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TAC1—allergic rhinitis	8.04e-06	0.00206	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TAC1—allergic rhinitis	7.87e-06	0.00202	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—NFKB1—allergic rhinitis	7.7e-06	0.00198	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL5—allergic rhinitis	7.53e-06	0.00193	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL5—allergic rhinitis	7.48e-06	0.00192	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CYSLTR1—allergic rhinitis	7.38e-06	0.0019	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL5—allergic rhinitis	7.32e-06	0.00188	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL11—allergic rhinitis	7.13e-06	0.00183	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CYSLTR1—allergic rhinitis	6.82e-06	0.00175	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CYSLTR1—allergic rhinitis	6.77e-06	0.00174	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CYSLTR1—allergic rhinitis	6.63e-06	0.0017	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL11—allergic rhinitis	6.59e-06	0.00169	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TAC1—allergic rhinitis	6.57e-06	0.00169	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL11—allergic rhinitis	6.54e-06	0.00168	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL11—allergic rhinitis	6.4e-06	0.00164	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTGDR2—allergic rhinitis	6.4e-06	0.00164	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL5—allergic rhinitis	6.11e-06	0.00157	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TAC1—allergic rhinitis	5.97e-06	0.00153	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TAC1—allergic rhinitis	5.71e-06	0.00146	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTGDR2—allergic rhinitis	5.56e-06	0.00143	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL5—allergic rhinitis	5.55e-06	0.00142	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL5—allergic rhinitis	5.31e-06	0.00136	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TAC1—allergic rhinitis	5.18e-06	0.00133	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CYSLTR1—allergic rhinitis	5.02e-06	0.00129	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL11—allergic rhinitis	4.85e-06	0.00125	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL5—allergic rhinitis	4.82e-06	0.00124	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TAC1—allergic rhinitis	4.79e-06	0.00123	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TAC1—allergic rhinitis	4.75e-06	0.00122	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TAC1—allergic rhinitis	4.65e-06	0.00119	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL5—allergic rhinitis	4.45e-06	0.00114	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL5—allergic rhinitis	4.42e-06	0.00113	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CYSLTR1—allergic rhinitis	4.36e-06	0.00112	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL5—allergic rhinitis	4.32e-06	0.00111	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NFKB1—allergic rhinitis	4.32e-06	0.00111	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL11—allergic rhinitis	4.21e-06	0.00108	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TGFB1—allergic rhinitis	3.6e-06	0.000923	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TAC1—allergic rhinitis	3.53e-06	0.000905	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL5—allergic rhinitis	3.28e-06	0.000841	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SMAD3—allergic rhinitis	3.13e-06	0.000804	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SMAD3—allergic rhinitis	3.11e-06	0.000798	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TAC1—allergic rhinitis	3.06e-06	0.000786	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SMAD3—allergic rhinitis	3.04e-06	0.000781	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL5—allergic rhinitis	2.85e-06	0.00073	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SMAD3—allergic rhinitis	2.31e-06	0.000592	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SMAD3—allergic rhinitis	2e-06	0.000514	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NFKB1—allergic rhinitis	1.59e-06	0.000409	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NFKB1—allergic rhinitis	1.58e-06	0.000405	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NFKB1—allergic rhinitis	1.55e-06	0.000397	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—allergic rhinitis	1.33e-06	0.00034	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—allergic rhinitis	1.32e-06	0.000338	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—allergic rhinitis	1.29e-06	0.000331	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NFKB1—allergic rhinitis	1.17e-06	0.000301	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NFKB1—allergic rhinitis	1.02e-06	0.000261	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—allergic rhinitis	9.77e-07	0.000251	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—allergic rhinitis	8.48e-07	0.000218	CbGpPWpGaD
